Personalized cancer immunotherapy

Immune biomarkers and combination immunotherapy

Yutaka Kawakami, Boryana Popivanova, Sunthamala Nuchsupha, Taeko Hayakawa, Kenta Nakamura, Haruna Nagumo, Ikumi Katano, Tomonari Kinoshita, Kinya Tsubota, Hajime Kamijuku, Naoshi Kawamura, Junichiro Miyazaki, Ryosuke Satomi, Juri Sugiyama, Hiroshi Nishio, Shinobu Noji, Chie Kudo-Saito, Nobuo Tsukamoto, Toshiharu Sakurai, Tomonobu Fujita & 1 others Tomonori Yaguchi

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Cancer immunotherapies utilizing tumor-specific T-cell responses, immune-checkpoint blockade, and T-cell-based adoptive cell therapy, have recently shown durable responses in advanced patients with various cancers. However, there are still cancer types and patients who do not respond to these immunotherapies. Pretreatment immune status varies in cancer patients, and it correlates with prognosis after various cancer therapies including immunotherapy. The differential T-cell response is defined by positive (e.g., number of immunogenic mutated peptides derived from mainly passenger DNA mutations in cancer cells, polymorphisms of immune-related genes of patients) and negative (e.g., oncogene activation including driver DNA mutations) immune pathways along with environmental factors (e.g., intestinal microbiota, diet, smoking, infection history). These factors could be biomarkers for selection of the patients who are likely to respond to immunotherapy and furthermore could be therapeutic targets to improve efficacy of immunotherapy possibly by combination immunotherapy with interventions on multiple key regulation points in the antitumor T-cell responses. Personalized combination immunotherapy based on the evaluation of T-cell immune status is a promising strategy for cancer treatment.

Original languageEnglish
Title of host publicationImmunotherapy of Cancer
Subtitle of host publicationAn Innovative Treatment Comes of Age
PublisherSpringer Japan
Pages349-358
Number of pages10
ISBN (Electronic)9784431550310
ISBN (Print)9784431550303
DOIs
Publication statusPublished - 2016 Feb 22

Fingerprint

Immunotherapy
Biomarkers
Neoplasms
T-Lymphocytes
Mutation
DNA
Cell- and Tissue-Based Therapy
Oncogenes
Patient Selection
Therapeutics
Smoking
Diet
Peptides
Infection
Genes

Keywords

  • Biomarkers
  • Cancer immunopathology
  • Cancer immunotherapy
  • Combination therapy
  • Personalized therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kawakami, Y., Popivanova, B., Nuchsupha, S., Hayakawa, T., Nakamura, K., Nagumo, H., ... Yaguchi, T. (2016). Personalized cancer immunotherapy: Immune biomarkers and combination immunotherapy. In Immunotherapy of Cancer: An Innovative Treatment Comes of Age (pp. 349-358). Springer Japan. https://doi.org/10.1007/978-4-431-55031-0_24

Personalized cancer immunotherapy : Immune biomarkers and combination immunotherapy. / Kawakami, Yutaka; Popivanova, Boryana; Nuchsupha, Sunthamala; Hayakawa, Taeko; Nakamura, Kenta; Nagumo, Haruna; Katano, Ikumi; Kinoshita, Tomonari; Tsubota, Kinya; Kamijuku, Hajime; Kawamura, Naoshi; Miyazaki, Junichiro; Satomi, Ryosuke; Sugiyama, Juri; Nishio, Hiroshi; Noji, Shinobu; Kudo-Saito, Chie; Tsukamoto, Nobuo; Sakurai, Toshiharu; Fujita, Tomonobu; Yaguchi, Tomonori.

Immunotherapy of Cancer: An Innovative Treatment Comes of Age. Springer Japan, 2016. p. 349-358.

Research output: Chapter in Book/Report/Conference proceedingChapter

Kawakami, Y, Popivanova, B, Nuchsupha, S, Hayakawa, T, Nakamura, K, Nagumo, H, Katano, I, Kinoshita, T, Tsubota, K, Kamijuku, H, Kawamura, N, Miyazaki, J, Satomi, R, Sugiyama, J, Nishio, H, Noji, S, Kudo-Saito, C, Tsukamoto, N, Sakurai, T, Fujita, T & Yaguchi, T 2016, Personalized cancer immunotherapy: Immune biomarkers and combination immunotherapy. in Immunotherapy of Cancer: An Innovative Treatment Comes of Age. Springer Japan, pp. 349-358. https://doi.org/10.1007/978-4-431-55031-0_24
Kawakami Y, Popivanova B, Nuchsupha S, Hayakawa T, Nakamura K, Nagumo H et al. Personalized cancer immunotherapy: Immune biomarkers and combination immunotherapy. In Immunotherapy of Cancer: An Innovative Treatment Comes of Age. Springer Japan. 2016. p. 349-358 https://doi.org/10.1007/978-4-431-55031-0_24
Kawakami, Yutaka ; Popivanova, Boryana ; Nuchsupha, Sunthamala ; Hayakawa, Taeko ; Nakamura, Kenta ; Nagumo, Haruna ; Katano, Ikumi ; Kinoshita, Tomonari ; Tsubota, Kinya ; Kamijuku, Hajime ; Kawamura, Naoshi ; Miyazaki, Junichiro ; Satomi, Ryosuke ; Sugiyama, Juri ; Nishio, Hiroshi ; Noji, Shinobu ; Kudo-Saito, Chie ; Tsukamoto, Nobuo ; Sakurai, Toshiharu ; Fujita, Tomonobu ; Yaguchi, Tomonori. / Personalized cancer immunotherapy : Immune biomarkers and combination immunotherapy. Immunotherapy of Cancer: An Innovative Treatment Comes of Age. Springer Japan, 2016. pp. 349-358
@inbook{060fec66593a4059860c9b50dd366e68,
title = "Personalized cancer immunotherapy: Immune biomarkers and combination immunotherapy",
abstract = "Cancer immunotherapies utilizing tumor-specific T-cell responses, immune-checkpoint blockade, and T-cell-based adoptive cell therapy, have recently shown durable responses in advanced patients with various cancers. However, there are still cancer types and patients who do not respond to these immunotherapies. Pretreatment immune status varies in cancer patients, and it correlates with prognosis after various cancer therapies including immunotherapy. The differential T-cell response is defined by positive (e.g., number of immunogenic mutated peptides derived from mainly passenger DNA mutations in cancer cells, polymorphisms of immune-related genes of patients) and negative (e.g., oncogene activation including driver DNA mutations) immune pathways along with environmental factors (e.g., intestinal microbiota, diet, smoking, infection history). These factors could be biomarkers for selection of the patients who are likely to respond to immunotherapy and furthermore could be therapeutic targets to improve efficacy of immunotherapy possibly by combination immunotherapy with interventions on multiple key regulation points in the antitumor T-cell responses. Personalized combination immunotherapy based on the evaluation of T-cell immune status is a promising strategy for cancer treatment.",
keywords = "Biomarkers, Cancer immunopathology, Cancer immunotherapy, Combination therapy, Personalized therapy",
author = "Yutaka Kawakami and Boryana Popivanova and Sunthamala Nuchsupha and Taeko Hayakawa and Kenta Nakamura and Haruna Nagumo and Ikumi Katano and Tomonari Kinoshita and Kinya Tsubota and Hajime Kamijuku and Naoshi Kawamura and Junichiro Miyazaki and Ryosuke Satomi and Juri Sugiyama and Hiroshi Nishio and Shinobu Noji and Chie Kudo-Saito and Nobuo Tsukamoto and Toshiharu Sakurai and Tomonobu Fujita and Tomonori Yaguchi",
year = "2016",
month = "2",
day = "22",
doi = "10.1007/978-4-431-55031-0_24",
language = "English",
isbn = "9784431550303",
pages = "349--358",
booktitle = "Immunotherapy of Cancer",
publisher = "Springer Japan",

}

TY - CHAP

T1 - Personalized cancer immunotherapy

T2 - Immune biomarkers and combination immunotherapy

AU - Kawakami, Yutaka

AU - Popivanova, Boryana

AU - Nuchsupha, Sunthamala

AU - Hayakawa, Taeko

AU - Nakamura, Kenta

AU - Nagumo, Haruna

AU - Katano, Ikumi

AU - Kinoshita, Tomonari

AU - Tsubota, Kinya

AU - Kamijuku, Hajime

AU - Kawamura, Naoshi

AU - Miyazaki, Junichiro

AU - Satomi, Ryosuke

AU - Sugiyama, Juri

AU - Nishio, Hiroshi

AU - Noji, Shinobu

AU - Kudo-Saito, Chie

AU - Tsukamoto, Nobuo

AU - Sakurai, Toshiharu

AU - Fujita, Tomonobu

AU - Yaguchi, Tomonori

PY - 2016/2/22

Y1 - 2016/2/22

N2 - Cancer immunotherapies utilizing tumor-specific T-cell responses, immune-checkpoint blockade, and T-cell-based adoptive cell therapy, have recently shown durable responses in advanced patients with various cancers. However, there are still cancer types and patients who do not respond to these immunotherapies. Pretreatment immune status varies in cancer patients, and it correlates with prognosis after various cancer therapies including immunotherapy. The differential T-cell response is defined by positive (e.g., number of immunogenic mutated peptides derived from mainly passenger DNA mutations in cancer cells, polymorphisms of immune-related genes of patients) and negative (e.g., oncogene activation including driver DNA mutations) immune pathways along with environmental factors (e.g., intestinal microbiota, diet, smoking, infection history). These factors could be biomarkers for selection of the patients who are likely to respond to immunotherapy and furthermore could be therapeutic targets to improve efficacy of immunotherapy possibly by combination immunotherapy with interventions on multiple key regulation points in the antitumor T-cell responses. Personalized combination immunotherapy based on the evaluation of T-cell immune status is a promising strategy for cancer treatment.

AB - Cancer immunotherapies utilizing tumor-specific T-cell responses, immune-checkpoint blockade, and T-cell-based adoptive cell therapy, have recently shown durable responses in advanced patients with various cancers. However, there are still cancer types and patients who do not respond to these immunotherapies. Pretreatment immune status varies in cancer patients, and it correlates with prognosis after various cancer therapies including immunotherapy. The differential T-cell response is defined by positive (e.g., number of immunogenic mutated peptides derived from mainly passenger DNA mutations in cancer cells, polymorphisms of immune-related genes of patients) and negative (e.g., oncogene activation including driver DNA mutations) immune pathways along with environmental factors (e.g., intestinal microbiota, diet, smoking, infection history). These factors could be biomarkers for selection of the patients who are likely to respond to immunotherapy and furthermore could be therapeutic targets to improve efficacy of immunotherapy possibly by combination immunotherapy with interventions on multiple key regulation points in the antitumor T-cell responses. Personalized combination immunotherapy based on the evaluation of T-cell immune status is a promising strategy for cancer treatment.

KW - Biomarkers

KW - Cancer immunopathology

KW - Cancer immunotherapy

KW - Combination therapy

KW - Personalized therapy

UR - http://www.scopus.com/inward/record.url?scp=85030170747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030170747&partnerID=8YFLogxK

U2 - 10.1007/978-4-431-55031-0_24

DO - 10.1007/978-4-431-55031-0_24

M3 - Chapter

SN - 9784431550303

SP - 349

EP - 358

BT - Immunotherapy of Cancer

PB - Springer Japan

ER -